IRIDEX to Report Third Quarter 2020 Financial Results on November 9, 2020

Rhea-AI Summary

IRIDEX Corporation (Nasdaq: IRIX) will release its Q3 2020 financial results after trading hours on November 9, 2020. The management team will host a conference call at 2:00 p.m. PT to discuss the results. Interested investors can join via a dedicated phone line or through a live webcast available on the company’s website. IRIDEX is a leading developer of laser-based medical systems for the ophthalmology market, providing innovative treatments for conditions like glaucoma and diabetic macular edema through its proprietary MicroPulse® technology.

Positive

• IRIDEX is poised to report its Q3 2020 results, signaling ongoing financial operations.
• The company has a robust product line targeting significant eye conditions, including glaucoma and diabetic macular edema.

Negative

• None.

MOUNTAIN VIEW, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the close of trading on Monday, November 9, 2020. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 5860026. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.

About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at www.iridex.com.

Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@iridex.com

Media Contact:
Jamie Hall
Pascale Communications, LLC.
(724) 417-0167
pr@iridex.com

FAQ

When will IRIDEX announce its Q3 2020 financial results?

IRIDEX will announce its Q3 2020 financial results on November 9, 2020.

What time is the IRIDEX Q3 2020 earnings call?

The IRIDEX Q3 2020 earnings call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.

How can I listen to the IRIDEX conference call?

Investors can listen to the IRIDEX conference call by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 5860026.

Where can I find the IRIDEX earnings call webcast?

The live and archived webcast of the IRIDEX earnings call will be available in the 'Investors' section of the company's website.